For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Safety overview in phase 3 studies

Across 2 phase 3 studies, Tafinlar + Mekinist was well tolerated, with low rates of grade 3/4 adverse events and related discontinuations

Tafinlar + Mekinist demonstrated similar incidences of adverse events and discontinuations due to adverse events compared with BRAF inhibitor monotherapy1,2

Tafinlar® (dabrafenib) + Mekinist® (trametinib) adverse events compared with other therapies

  • Although the overall incidences of total and grade 3/4 AEs, as well as treatment discontinuations because of AEs, were similar between Tafinlar + Mekinist and BRAF inhibitor monotherapy, there were safety profile differences in the most common AEs and AEs of special interest1,2
  • Median duration of exposure in COMBI-v was 12.2 months with Tafinlar + Mekinist vs 6.7 months with vemurafenib1

AE, adverse event.

Safety information

References: 1. Robert C, Karaszewska B, Schachter J, et al. Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib + trametinib in patients with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Presented at: European Society for Medical Oncology; October 7-11, 2016; Copenhagen, Denmark. 2. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444-451.